Minireviews
Copyright ©The Author(s) 2023.
World J Diabetes. Jun 15, 2023; 14(6): 783-794
Published online Jun 15, 2023. doi: 10.4239/wjd.v14.i6.783
Table 1 Glycemic variability: Clinical relevance
Ref.
Patient population
Variability index
Reported results
Egi et al[13], 20067049 ICU patients, DM includedICU survivors vs ICU non-survivors
SDSD: 1.7 vs 2.3 mmol/L, P < 0.001
CVCV: 20 vs 26%, P < 0.001
Ali et al[14], 20081246 patients with sepsis, DM includedMortality crude odds ratio, 95%CI
GLIGLI: 1.25, 1.20-1.32, P < 0.001
MAGEMAGE: 1.12, 1.07-1.18, P < 0.001
SDSD: 1.16, 1.11-1.21, P < 0.001
Donati et al[15], 20141641 ICU patients, DM includedICU survivors vs ICU non-survivors
SDSD: 1.4 vs 1.7 mmol/L, P < 0.001
CVCV: 21 vs 23%, P < 0.001
GLIGLI: 50.1 vs 75.6 (mmol/L)2/h/wk, P < 0.001
MAGEMAGE: 2.4 vs 2.7 mmol/L, P < 0.001
No infection vs ICU-acquired infection
SDSD: 1.4 vs 1.6 mmol/L, P < 0.001
CVCV: 20 vs 23%, P < 0.001
GLIGLI: 44.6 vs 73.5 (mmol/L) 2/h/wk, P < 0.001
MAGEMAGE: 2.3 vs 2.7 mmol/L, P < 0.001
Akirov et al[16], 20198894 surgical patients, DM includedHospital LOS: Low GV vs High GV
SDDM SD: 7 vs 9 d, P < 0.001
SDNo DM SD: 7 vs 9 d, P < 0.001
CVDM CV: 7 vs 9 d, P < 0.001
CVNo DM: CV 7 vs 9 d, P < 0.001
30 d mortality: Low GV vs High GV
SDDM SD: 5% vs 8%, P < 0.05
SDNo DM SD: 3% vs 9%, P < 0.05
CVDM CV: 5% vs 9%, P < 0.05
CVNo DM CV: 3% vs 9%, P < 0.05